WORLDWIDE ACCESS TRADING DEVELOP LIMITED – Trademark Portfolio

Entity Type: 99

WORLDWIDE ACCESS TRADING DEVELOP LIMITED holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include MOOKUNMAX and MOOYSSDKE. The owner is based in HONG KONG.

RM D07, 8/F, KAI TAK FTY BUILDING, NO. 99 KING FUK STREET, SANPOKONG, KOWLOON

HONG KONG 999077 , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

WORLDWIDE ACCESS TRADING DEVELOP LIMITED's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does WORLDWIDE ACCESS TRADING DEVELOP LIMITED have?

WORLDWIDE ACCESS TRADING DEVELOP LIMITED has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does WORLDWIDE ACCESS TRADING DEVELOP LIMITED file in?

WORLDWIDE ACCESS TRADING DEVELOP LIMITED files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are WORLDWIDE ACCESS TRADING DEVELOP LIMITED's most well-known trademarks?

WORLDWIDE ACCESS TRADING DEVELOP LIMITED's registered trademark portfolio includes well-known marks such as MOOKUNMAX and MOOYSSDKE. These are among 2 currently registered trademarks in the portfolio.

What is WORLDWIDE ACCESS TRADING DEVELOP LIMITED's trademark registration success rate?

WORLDWIDE ACCESS TRADING DEVELOP LIMITED has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.